www.maketheconnection.

org
GCF (Gynecologic Cancer Foundation) Presentation
www.maketheconnection.org
www.cancer.org
www.maketheconnection.org
www.nccc-online.org
 1/Wright/p.21
20/abstract
conclusions

2/Bonnez/p.
576/Figure
12; p. 578/col
1/2

3/CCS/p 6/2

4/Sellors/Ch.
7/p.9/Figure
7.23.

1. Wright TC Jr, Cox JT, Massad LS, et al, for the ASCCP-Sponsored
Consensus Congress. JAMA. 2002;287:21202129. 2. Bonnez W. In:
Richman DD, Whitley RJ, Hayden FJ, eds. Washington, DC: American
Society for Microbiology Press; 2002:557596. 3. Canadian Cancer
Society. Cervical Cancer: What you need to know. Available at:
http://www.cancer.ca/vgn/images/portal/cit_86751114/63/40/151140772cw
1/Sellors/Ch _library_wyntk_cervical_en.pdf. Accessed March 13, 2006. 4. Reprinted
. 4/p. 1/ 1;
p.5/ 2 with permission from Sellors JW, Sankaranarayanan R, eds. Colposcopy
and Treatment of Cervical Intraepithelial Neoplasia. A Beginners Manual.
1/Sellors/Ch Lyon, France: International Agency for Research on Cancer; 2003.
. 7/p. 1/ 1;
p. 6/ 3,
www.maketheconnection.org
www.cdc.gov/std/HPV/STDFcat-HPV.htm
 1/Parham/p.
S14/Table 1.
2/Schink/p. 5/
col 2/2.
3/Uyar/p. 227/
abstract.
4/Kulasingam/p.
1754/Table 3.

2/Schink/p.
5/col 2/1.
5/Selvaggi/
p. 1506/col
1/1, 3.
6/Chacho/p.
137/col 2/5

1/Hewitt/p.
270/ col 1/1 1. Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analyses of the
2000 National Health Interview Survey. Prev Med. 2004;39:270-278.
2. Crum CP, Rivera MN. Vaccines for cervical cancer. Cancer J. 2003;9:368376.
3. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history
and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan.
2/Crum/p. Cancer. 2000;88:22832289.
368/col 4. Schink JC. Strategies for detecting cervical dysplasia: Visual inspection, spectroscopy, and
1/2; col speculoscopy. OBG Manag. 2003;(suppl):58.
5. Selvaggi SM. Implications of low diagnostic reproducibility of cervical cytologic and histologic
2/1 diagnoses. JAMA. 2001;285:15061508.
3/Sung/p. 6. Chacho MS, Mattie ME, Schwartz PE. Cytohistologic correlation rates between conventional
2285/col Papanicolaou smears and ThinPrep cervical cytology: A comparison. Cancer. 2003;99:135140.
7. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the early
2/3, 4 detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342362.
8. Uyar DS, Eltabbakh GH, Mount SL. Positive predictive value of liquid-based and conventional
cervical Papanicolaou smears reported as malignant. Gynecol Oncol. 2003;89:227232.
4/Schink/ p. 9. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in
5/ col 2/1. primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency
of referral. JAMA. 2002;288:17491757.
5/Selvaggi/
p. 1506/col
1/1, 3.
6/Chacho/
p. 137/col
American Cancer Detailed Guide. American Cancer Society Online
Publication. http://www.cancer.org
The next issue we wanted to address was how to make sure that we get a
cancer prevention indication at launch. Such a claim will be critical to the
success of the vaccine.
Well, lets go back to the schematic of HPV infection natural history in
women. Cervical cancer is all the way on the right here. And if you add up
all the years between initial HPV infection and cancer, you get to 20 years
or so. Too long for a clinical trial. Also, we couldnt allow women to remain
untreated and to develop cancer in a clinical trial trial participants would
have to get the very best health care during the study including intensive
The picture on your left is the magnified image of a
normal cervix after the application of Acetic acid.

The picture to your right is the magnified image of a

2/Wiley/p.
S211/col 2/1

3/Maw/p.
574/col 2/5;
p. 574/Table
4; p. 575/
Table 5

4/Kodner/p.
2339/Table 3

4/Kodner/p.
2339/Table 3

References
1. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: Diagnosis, treatment,
and prevention. Clin Infect Dis. 2002;35(suppl 2):S210S224.
2. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts:
Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS. 1998;9:571
578.
1/Wiley/p. 3. Soper DE. Genitourinary infections and sexually transmitted diseases. In: Berek
S211/col 2/1 JS, ed. Novaks Gynecology. 13th ed. Philadelphia, Pa: Lippincott Williams & Wilkins;
2002:453470.
4. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician.
2/Maw/p.
574/col 2004;70:23352342, 23452346.
2/5; p.
574/Table 4;
p. 575/Table
5; p. 571/
abstract /3
1/Sellors/Ch
. 8/p. 4/ Photos
Figures 3.5 courtesy of
and 8.8 Dr. J.
Monsonego.

1. Reprinted with permission from Sellors JW, Sankaranarayanan R,

1/Sellors/Ch
. 8/p. 2/
5,6.
Stage I is carcinoma strictly confined to the cervix; extension to the uterine corpus should be
disregarded.
Stage IA: Invasive cancer identified only microscopically. All gross lesions even with superficial
invasion are stage Ib cancers. Invasion is limited to measured stromal invasion with a maximum depth
of 5 mm* and no wider than 7 mm. [Note: *The depth of invasion should not be more than 5 mm taken
from the base of the epithelium, either surface or glandular, from which it originates. Vascular space
involvement, either venous or lymphatic, should not alter the staging.]
Stage IA1: Measured invasion of the stroma no greater than 3 mm in depth and no wider than
7 mm diameter.
Stage IA2: Measured invasion of stroma greater than 3 mm but no greater than 5 mm in depth
and no wider than 7 mm in diameter.
Stage IB: Clinical lesions confined to the cervix or preclinical lesions greater than stage IA.
Stage IB1: Clinical lesions no greater than 4 cm in size.
Stage IB2: Clinical lesions greater than 4 cm in size.
Stage II is carcinoma that extends beyond the cervix but has not extended onto the pelvic wall. The
carcinoma involves the vagina, but not as far as the lower third.